These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18781960)

  • 1. Cardiovascular disease in patients with diabetic nephropathy.
    Aso Y
    Curr Mol Med; 2008 Sep; 8(6):533-43. PubMed ID: 18781960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia and cardiovascular disease in diabetic nephropathy.
    McFarlane SI; Salifu MO; Makaryus J; Sowers JR
    Curr Diab Rep; 2006 Jun; 6(3):213-8. PubMed ID: 16898574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end products and diabetic complications.
    Stitt AW; Jenkins AJ; Cooper ME
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of diabetic nephropathy in current nephrological practice.
    Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C
    Nephrol Dial Transplant; 2003 Sep; 18(9):1716-25. PubMed ID: 12937216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
    Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
    Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
    Yamagishi S; Matsui T; Ueda S; Nakamura K; Imaizumi T
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):236-40. PubMed ID: 17630950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.
    Tziomalos K; Athyros VG
    Rev Diabet Stud; 2015; 12(1-2):110-8. PubMed ID: 26676664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic nephropathy and cardiac disease].
    Gross JL; Silveiro SP; Canani LH; Friedman R; Leitão CB; Azevedo MJ
    Arq Bras Endocrinol Metabol; 2007 Mar; 51(2):244-56. PubMed ID: 17505631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of AGEs in diabetic nephropathy.
    Fukami K; Yamagishi S; Ueda S; Okuda S
    Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products and diabetic nephropathy.
    Thomas MC; Forbes JM; Cooper ME
    Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.
    Yamagishi S; Fukami K; Ueda S; Okuda S
    Curr Drug Targets; 2007 Aug; 8(8):952-9. PubMed ID: 17691932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant.
    Calviño J; Cigarran S; Gonzalez-Tabares L; Menendez N; Latorre J; Cillero S; Millan B; Cobelo C; Sanjurjo-Amado A; Quispe J; Garcia-Enriquez A; Carrero JJ
    PLoS One; 2018; 13(8):e0201118. PubMed ID: 30067789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy.
    Roumeliotis AK; Roumeliotis SK; Panagoutsos SA; Tsetsos F; Georgitsi M; Manolopoulos V; Paschou P; Passadakis PS
    Int Urol Nephrol; 2018 Feb; 50(2):321-329. PubMed ID: 29196930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications.
    Du MR; Ju GX; Li NS; Jiang JL
    J Cardiovasc Pharmacol; 2016 Oct; 68(4):322-326. PubMed ID: 27760067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic nephropathy and cardiovascular diseases.
    Czekalski S
    Rocz Akad Med Bialymst; 2005; 50():122-5. PubMed ID: 16358950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.